var data={"title":"Argatroban: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Argatroban: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5664?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=argatroban-drug-information\" class=\"drug drug_general\">see &quot;Argatroban: Drug information&quot;</a> and <a href=\"topic.htm?path=argatroban-patient-drug-information\" class=\"drug drug_patient\">see &quot;Argatroban: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998934\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anticoagulant, Thrombin Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998969\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=argatroban-drug-information\" class=\"drug drug_general\">see &quot;Argatroban: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heparin-induced thrombocytopenia:</b> Limited data available: Infants and Children &le;16 years: <b>Note:</b> Titration of maintenance dose must consider multiple factors including current argatroban dose, current aPTT, target aPTT, and clinical status of the patient. For specific uses, required maintenance dose is highly variable between patients. During the course of treatment, patient's dosing requirements may change as clinical status changes; critically ill patients and patients with hepatic dysfunction require lower dose; frequent dosage adjustments may be required in critical patients to maintain desired anticoagulant activity (Alsoufi 2004; Boshkov 2006; Keegan 2009). If argatroban therapy is used concurrently with or following FFP or a thrombolytic, some centers decrease dose by half (Alsoufi 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Initial dose</i>: 0.75 mcg/kg/minute (Madabushi 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Maintenance dose:</i> Measure aPTT after 2 hours; adjust dose until the steady-state aPTT is 1.5 to 3 times the initial baseline value, not exceeding 100 seconds; adjust in increments of 0.1 to 0.25 mcg/kg/minute for normal hepatic function; reduce dose in hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> A lower initial infusion rate may be needed in other pediatric patients with reduced clearance of argatroban (eg, patients with heart failure, multiple organ system failure, severe anasarca, postcardiac surgery or hepatic impairment). This precaution is based on adult studies of patients with these disease states who had reduced argatroban clearance.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion to oral anticoagulant</i>: Because there may be a combined effect on the INR when argatroban is combined with warfarin, loading doses of warfarin should not be used. Warfarin therapy should be started at the expected daily dose. Once combined INR on warfarin and argatroban is &gt;4, stop argatroban. Repeat INR measurement in 4 to 6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained. Another option is to use factor X levels to monitor the effect of warfarin anticoagulation. When factor X level is &lt;0.3, warfarin is considered therapeutic and at which time argatroban can be discontinued (Alsoufi 2004; Boshkov 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heparin-induced thrombocytopenia:</b> Continuous IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial dose:</i> 2 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Critically ill patients with normal hepatic function have become excessively anticoagulated with FDA approved or lower starting doses of argatroban. Doses between 0.15 to 1.3 mcg/kg/minute were required to maintain aPTTs in the target range (Reichert 2003). In a prospective, observational study of critically ill patients with multiple organ dysfunction (MODS) and suspected or proven HIT, an initial infusion dose of 0.2 mcg/kg/minute was found to be sufficient and safe in this population (Beiderlinden 2007). Consider reducing starting dose to 0.2 mcg/kg/minute in critically ill patients with MODS defined as a minimum number of two organ failures. Another report of a cardiac patient with anasarca secondary to acute renal failure had a reduction in argatroban clearance similar to patients with hepatic dysfunction. Reduced clearance may have been due to reduced liver perfusion (de Denus 2003). The American College of Chest Physicians has recommended an initial infusion rate of 0.5 to 1.2 mcg/kg/minute for patients with heart failure, MODS, severe anasarca, or postcardiac surgery (Linkins 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Obesity:</i> Pharmacokinetics and pharmacodynamics have not been evaluated prospectively in obese patients; however, retrospective data suggest using actual body weight to dose and that adjustment of initial dose is unnecessary in obesity (BMI up to 51 kg/m<sup>2</sup>) (Rice 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Maintenance dose:</i> Patient may not be at steady state but measure aPTT after 2 hours; adjust dose until the steady state aPTT is 1.5 to 3 times the initial baseline value, not exceeding 100 seconds; dosage should not exceed 10 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Conversion to oral anticoagulant:</i> Because there may be a combined effect on the INR when argatroban is combined with warfarin, loading doses of warfarin should not be used. Warfarin therapy should be started at the expected daily dose.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients receiving &le;2 mcg/kg/minute of argatroban: Argatroban therapy can be stopped when the combined INR on warfarin and argatroban is &gt;4; repeat INR measurement in 4 to 6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients receiving &gt;2 mcg/kg/minute of argatroban: Reduce dose of argatroban to 2 mcg/kg/minute; measure INR for argatroban and warfarin 4 to 6 hours after dose reduction; argatroban therapy can be stopped when the combined INR on warfarin and argatroban is &gt;4. Repeat INR measurement in 4 to 6 hours; if INR is below therapeutic level, argatroban therapy may be restarted. Repeat procedure daily until desired INR on warfarin alone is obtained.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> The American College of Chest Physicians suggests monitoring chromogenic factor X assay when transitioning from argatroban to warfarin (Garcia 2012) or overlapping administration of warfarin for a minimum of 5 days until INR is within target range; recheck INR after anticoagulant effect of argatroban has dissipated (Guyatt 2012). Factor X levels &lt;45% have been associated with INR values &gt;2 after the effects of argatroban have been eliminated (Arpino 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Percutaneous coronary intervention (PCI):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial:</i> Begin infusion of 25 mcg/kg/minute and administer bolus dose of 350 mcg/kg (over 3 to 5 minutes). ACT should be checked 5 to 10 minutes after bolus infusion; proceed with procedure if ACT &gt;300 seconds.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Obesity:</i> Pharmacokinetics and pharmacodynamics have not been evaluated prospectively in obese patients; however, retrospective data suggest using actual body weight to dose and that adjustment of initial dose is unnecessary in obesity (BMI up to 51 kg/m<sup>2</sup>) (Hursting 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Following initial bolus:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ACT &lt;300 seconds: Give an additional 150 mcg/kg bolus, and increase infusion rate to 30 mcg/kg/minute (recheck ACT in 5 to 10 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ACT &gt;450 seconds: Decrease infusion rate to 15 mcg/kg/minute (recheck ACT in 5 to 10 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Once a therapeutic ACT (300 to 450 seconds) is achieved, infusion should be continued at this dose for the duration of the procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>If dissection, impending abrupt closure, thrombus formation during PCI, or inability to achieve ACT &gt;300 seconds:</i> An additional bolus of 150 mcg/kg, followed by an increase in infusion rate to 40 mcg/kg/minute may be administered (recheck ACT after each additional bolus or change in infusion rate).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Post-PCI anticoagulation, if required, may be achieved by continuing infusion at a reduced dose of 2 mcg/kg/minute, with close monitoring of aPTT; adjust infusion rate as needed. Recheck ACT after each additional bolus or change in infusion rate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to severe impairment: All patients: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: Dialyzable: Yes; ~20% removed over 4 hours during hemodialysis (NCS/SCCM [Frontera 2016]); removal during hemodialysis and continuous venovenous hemofiltration did not alter clinical efficacy when used for anticoagulation in renal replacement therapy (Tang 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Decreased clearance is seen with hepatic impairment; dose should be reduced.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents &le;16 years: Heparin-induced thrombocytopenia; IV continuous infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: 0.2 mcg/kg/minute (Young 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Measure aPTT after 2 hours; adjust dose until the steady-state aPTT is 1.5 to 3 times the initial baseline value, not exceeding 100 seconds; adjust in increments of &le;0.05 mcg/kg/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Moderate hepatic impairment: IV continuous infusion: Initial dose: 0.5 mcg/kg/minute; monitor aPTT closely; adjust dose as clinically needed. <b>Note:</b> During PCI, avoid use in patients with elevations of ALT/AST (&gt;3 times ULN); the use of argatroban in these patients has not been evaluated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136522\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/125 mL (125 mL); 250 mg/250 mL (250 mL); 250 mg/2.5 mL (2.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/50 mL (50 mL); 250 mg/2.5 mL (2.5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136507\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998974\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV use only. For HIT, administer by continuous IV infusion. For PCI, administer by IV infusion and bolus dose over 3 to 5 minutes through a large bore intravenous line.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471318\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 1000 <b>mcg</b>/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136540\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vials, 2.5 mL (100 mg/mL) concentrate: Prior to use, store vial in original carton at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&ordm;C to 30&ordm;C (59&ordm;F to 86&deg;F). Do not freeze. Protect from light. The prepared solution, diluted in D5W, LR, or NS, is stable for 24 hours at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) in ambient indoor light. Do not expose prepared solutions to direct sunlight. Prepared solutions that are protected from light and kept at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) or under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) are stable for up to 96 hours. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Premixed vials (50 mL or 125 mL) and single-use bags for infusion (1 mg/mL): Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Do not refrigerate or freeze. Protect from light. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998935\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT) (FDA approved in adults); anticoagulant for percutaneous coronary intervention (PCI) in patients who have or are at risk for thrombosis-associated HIT (FDA approved in adults). Has also been used in pediatric patients with HIT requiring anticoagulation (eg, procedural anticoagulation including cardiac catheterization, extracorporeal membrane oxygenation [ECMO], and hemodialysis/hemofiltration)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136573\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Argatroban may be confused with Aggrastat, Orgaran</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136571\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As with all anticoagulants, bleeding is the major adverse effect of argatroban. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the intensity of anticoagulation and patient susceptibility.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Cardiovascular: Angina pectoris, bradycardia, cardiac arrest, chest pain (PCI related), coronary occlusion, hypotension, ischemic heart disease, myocardial infarction (PCI), thrombosis, vasodilation, ventricular tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache, intracranial hemorrhage, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermatological reaction (bullous eruption, rash)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, gastrointestinal hemorrhage, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Genitourinary tract hemorrhage (including hematuria)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Brachial bleeding, decreased hematocrit, decreased hemoglobin, groin bleeding, minor hemorrhage (CABG related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain (PCI related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea, hemoptysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Aortic valve stenosis, bleeding at injection site (or access site; minor), hypersensitivity reaction, local hemorrhage (limb and below-the-knee stump), pulmonary edema, retroperitoneal bleeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136527\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to argatroban or any component of the formulation; major bleeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136511\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bleeding: The most common complication is bleeding and can occur at any site in the body. Use extreme caution in patients with hematologic conditions associated with increased bleeding (eg, congenital or acquired bleeding disorders, GI lesions); recent puncture of large vessels or organ biopsy; spinal anesthesia; immediately following lumbar puncture; recent cerebrovascular accident (CVA), stroke, intracerebral surgery, or other neuraxial procedure; severe hypertension; renal impairment; recent major surgery; recent major bleeding (intracranial, GI, intraocular, or pulmonary). Monitor for signs and symptoms of bleeding. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Airway, skin, and generalized hypersensitivity reactions have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage reduction is necessary; may require &gt;4 hours to achieve full reversal of anticoagulant effects. Avoid use during PCI in patients with clinically significant hepatic impairment or elevations of ALT/AST &ge;3 times ULN (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Critically-ill patients: Use with caution in critically-ill patients; reduced clearance may require dosage reduction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25819765\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The appropriate goals of anticoagulation and duration of treatment in pediatric patients have not been established. In pediatric trials, hypokalemia and abdominal pain were reported (Young, 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136560\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136515\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13081&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136531\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Information related to argatroban in pregnancy is limited. Use of parenteral direct thrombin inhibitors in pregnancy should be limited to those women who have severe allergic reactions to heparin, including heparin-induced thrombocytopenia, and who cannot receive danaparoid (Guyatt 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998976\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">HIT: Obtain baseline aPTT prior to start of therapy. Check aPTT 2 hours after start of therapy and any dosage adjustment. Monitor hemoglobin, hematocrit, platelets, signs and symptoms of bleeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136510\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A direct, highly-selective thrombin inhibitor. Reversibly binds to the active thrombin site of free and clot-associated thrombin. Inhibits fibrin formation; activation of coagulation factors V, VIII, and XIII; activation of protein C; and platelet aggregation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136526\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Immediate </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 174 mL/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Albumin: 20%; alpha<sub>1</sub>-acid glycoprotein: 34% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via hydroxylation and aromatization (major route). Metabolism via CYP3A4/5 (minor route) to four metabolites. Unchanged argatroban is the major plasma component. Plasma concentration of metabolite M1 is 0% to 20% of the parent drug and is three- to five-fold weaker.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 39 to 51 minutes; Hepatic impairment: 181 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Steady-state: 1 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~65%; 14% unchanged); urine (~22%; 16% unchanged); low quantities of metabolites M2-4 in urine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pediatric patients (seriously ill): 0.16 L/kg/hour; 50% lower than healthy adults </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Pediatric patients (seriously ill with elevated bilirubin due to hepatic impairment or cardiac complications; n=4): 0.03 L/kg/hour; 80% lower than pediatric patients with normal bilirubin </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adult: 0.31 L/kg/hour (5.1 mL/kg/minute); hepatic impairment: 1.9 mL/kg/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F998982\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Molecular weight: 526.66; argatroban is a synthetic anticoagulant (direct thrombin inhibitor) derived from L-arginine. Increases in aPTT, ACT, PT, INR, and TT occur in a dose-dependent fashion with increasing doses of argatroban. Adult studies have established the use of aPTT for patients with HIT and ACT for patients with PCI procedures. Therapeutic ranges for PT, INR, and TT have not been identified.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A reversal agent to argatroban is not available. Should life-threatening bleeding occur, discontinue argatroban immediately, obtain an aPTT and other coagulation tests, and provide symptomatic and supportive care.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Infants and Children &le;16 years: Doses reported in the literature for infants and children with HIT for procedural anticoagulation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cardiac Catheterization: </b> Dose not established; the following doses have been used in limited reports: Initial IV bolus dose: 150-250 mcg/kg, followed by continuous IV infusion at an initial rate 5-15 mcg/kg/minute; one case series adjusted the continuous infusion dose to maintain target ACT &gt;300 seconds (n=4). <b>Note:</b> Data is limited to an open-labeled study of a mixed population that included six pediatric cardiac catheterization patients and case reports/series (n=4 patients) [Alsoufi, 2004; GlaxoSmithKline Result Summary, 2007 (manufacturer unpublished data); Young, 2007]. Further studies are required before these doses can be recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ECMO: </b> Dose not established; data is limited to an open-labeled study of a mixed population that included one infant on ECMO, published and submitted abstracts, and case reports/series (n=16 patients) [Alsoufi, 2004; GlaxoSmithKline Result Summary, 2007 (manufacturer unpublished data); Hursting, 2006; Potter, 2007; Tcheng, 2004]. Further studies are required before these doses can be recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The reported argatroban doses used to prime  the ECMO circuit have varied widely; more recent reports utilize an ECMO priming dose between 30-50 mcg based upon patient's clinical status and ACT, followed by a continuous IV infusion at an initial rate of 0.5-2 mcg/kg/minute; continuous infusion doses were adjusted to maintain target ACT of at least 200 seconds; reported ACT target ranges varied from 160-300 seconds or aPTT 2 times initial baseline value. Dosing requirements ranging from 0.1-24 mcg/kg/minute have been reported.  If patient not previously anticoagulated on heparin prior to starting argatroban, an initial bolus dose may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hemodialysis/Hemofiltration: </b> Dose not established; clinical data limited to case series/reports (Alsoufi, 2004; Hursting, 2006; Young, 2007). Further studies are required before these doses can be recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following doses have been used in limited reports: IV continuous infusion: Initial dose:  0.5-2 mcg/kg/minute; infusions were adjusted to maintain target ACT at least &gt;160 seconds or aPTT &gt;50 seconds; when reported, ACT target ranges were 160-200 seconds and aPTT 50-75 seconds. Reported dosing requirements were 0.1-2 mcg/kg/minute. If patient not previously anticoagulated on heparin prior to starting argatroban, an initial bolus dose may be required; initial bolus doses of 65 mcg/kg and 250 mcg/kg have each been reported.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136530\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Argatroban in Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/250 mL (250 mL): $953.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Argatroban Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/50 mL (50 mL): $272.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/2.5 mL (2.5 mL): $612.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539819\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arganova (NL);</li>\n      <li>Argata (AT);</li>\n      <li>Argatra (DE);</li>\n      <li>Da Bei (CN);</li>\n      <li>Exembol (GB);</li>\n      <li>Novastan (CN, DK, IT, JP, KR, NO, SE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alsoufi B, Boshkov LK, Kirby A, et al, &quot;Heparin-Induced Thrombocytopenia (HIT) in Pediatric Cardiac Surgery: An Emerging Cause of Morbidity and Mortality,&quot; <i>Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu</i>, 2004, 7:155-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/15283365/pubmed\" target=\"_blank\" id=\"15283365\">15283365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Argatroban [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Argatroban [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arpino PA, Demirjian Z, and Van Cott EM, &ldquo;Use of the Chromogenic Factor X Assay to Predict the International Normalized Ratio in Patients Transitioning From Argatroban to Warfarin,&rdquo; <i>Pharmacotherapy</i>, 2005, 25(2):157-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/15767231/pubmed\" target=\"_blank\" id=\"15767231\">15767231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beiderlinden M, Treschan TA, Gorlinger K, et al, &ldquo;Argatroban Anticoagulation in Critically Ill Patients,&rdquo; <i>Ann Pharmacother</i>, 2007, 41(5):749-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/17440009/pubmed\" target=\"_blank\" id=\"17440009\">17440009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boshkov LK, Kirby A, Shen I, et al, &quot;Recognition and Management of Heparin-Induced Thrombocytopenia in Pediatric Cardiopulmonary Bypass Patients,&quot; <i>Ann Thorac Surg</i>, 2006, 81(6):S2355-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/16731103/pubmed\" target=\"_blank\" id=\"16731103\">16731103</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chan VH, Monagle P, Massicotte P, Chan AK. Novel paediatric anticoagulants: a review of the current literature. <i>Blood Coagul Fibrinolysis</i>. 2010;21(2):144-151.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/20135753/pubmed\" target=\"_blank\" id=\"20135753\">20135753</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Denus S and Spinler SA, &ldquo;Decreased Argatroban Clearance Unaffected by Hemodialysis in Anasarca,&rdquo; <i>Ann Pharmacother</i>, 2003, 37(9):1237-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/12921506/pubmed\" target=\"_blank\" id=\"12921506\">12921506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):24-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/22315264/pubmed\" target=\"_blank\" id=\"22315264\">22315264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    GlaxoSmithKline Result Summary, Study No: SKF105043/013, &quot;An Open-Label Study of Argatroban Injection to Evaluate the Safety and Effectiveness in Pediatric Patients Requiring Anticoagulation Alternatives to Heparin,&quot; July 2, 2007. Available at: http://www.gsk-clinicalstudyregister.com/files/pdf/22691.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hirsh J, Guyatt G, Albers GW, et al, &ldquo;Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&rdquo; <i>Chest</i>, 2008, 133(6 Suppl):71-109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/18574259/pubmed\" target=\"_blank\" id=\"18574259\">18574259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hursting MJ, Dubb J, and Verme-Gibboney CN, &quot;Argatroban Anticoagulation in Pediatric Patients: A Literature Analysis,&quot; <i>J Pediatr Hematol Oncol</i>, 2006, 28(1):4-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/16394885/pubmed\" target=\"_blank\" id=\"16394885\">16394885</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hursting NJ and Jang IK, &quot;Impact of Renal Function on Argatroban Therapy During Percutaneous Coronary Intervention,&quot; <i>J Thromb Thrombolysis</i>, 2010 29(1):1-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/19504050/pubmed\" target=\"_blank\" id=\"19504050\">19504050</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keegan SP, Gallagher EM, Ernst NE, Young EJ, Mueller EW. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia.<i> Ann Pharmacother</i>. 2009;43(1):19-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/19116377/pubmed\" target=\"_blank\" id=\"19116377\">19116377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Linkins L, Dans AL, Moores LK, et al, &ldquo;Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):e495-530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/22315270/pubmed\" target=\"_blank\" id=\"22315270\">22315270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Madabushi R, Cox DS, Hossain M, et al. Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. <i>J Clin Pharmacol</i>. 2011;51(1):19-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/20421511/pubmed\" target=\"_blank\" id=\"20421511\">20421511</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Potter KE, Raj A, and Sullivan JE, &quot;Argatroban for Anticoagulation in Pediatric Patients With Heparin-Induced Thrombocytopenia Requiring Extracorporeal Life Support,&quot; <i>J Pediatr Hematol Oncol</i>, 2007, 29(4):265-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/17414571/pubmed\" target=\"_blank\" id=\"17414571\">17414571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reichert MG, MacGregor DA, Kincaid EH, et al, &quot;Excessive Argatroban Anticoagulation for Heparin-Induced Thrombocytopenia,&quot; <i>Ann Pharmacother</i>, 2003, 37(5):652-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/12708939/pubmed\" target=\"_blank\" id=\"12708939\">12708939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rice L, Hursting MJ, Baillie GM, et al, &ldquo;Argatroban Anticoagulation in Obese Versus Nonobese Patients: Implications for Treating Heparin-Induced Thrombocytopenia,&rdquo; <i>J Clin Pharmacol</i>, 2007, 47(8):1028-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/17525167/pubmed\" target=\"_blank\" id=\"17525167\">17525167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott LK, Grier LR, and Conrad SA, &quot;Heparin-Induced Thrombocytopenia in a Pediatric Patient Receiving Extracorporeal Membrane Oxygenation Managed With Argatroban,&quot; <i>Pediatr Crit Care Med</i>, 2006, 7(5):473-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/16807510/pubmed\" target=\"_blank\" id=\"16807510\">16807510</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tang IY, Cox DS, Patel K, et al, &ldquo;Argatroban and Renal Replacement Therapy in Patients With Heparin-Induced Thrombocytopenia,&rdquo; <i>Ann Pharmacother</i>, 2005, 39(2):231-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/15632219/pubmed\" target=\"_blank\" id=\"15632219\">15632219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tcheng WY and Wong W, &quot;Successful Use of Argatroban in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin,&quot; <i>Blood</i>, 2004,104:107b-108b.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Young G and Boshkov L, &quot;Prospective Study of Direct Thrombin Inhibition With Argatroban in Pediatric Patients Requiring Non-Heparin Anticoagulation,&quot; <i>Blood</i>, 2007, 110.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Young G, Boshkov LK, Sullivan JE, et al. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. <i>Pediatr Blood Cancer</i>. 2011;56(7):1103-1109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/21488155/pubmed\" target=\"_blank\" id=\"21488155\">21488155</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Young G, &quot;New Anticoagulants in Children,&quot; <i>Hematology Am Soc Hematol Educ Program</i>, 2008, 245-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/argatroban-pediatric-drug-information/abstract-text/19074090/pubmed\" target=\"_blank\" id=\"19074090\">19074090</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13081 Version 127.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F998934\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F998969\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F136522\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F136507\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F998974\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14471318\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F136540\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F998935\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F136573\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F136571\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F136527\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F136511\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25819765\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F136560\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F136515\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F136531\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F998976\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F136510\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F136526\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F998982\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F136530\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539819\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13081|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=argatroban-drug-information\" class=\"drug drug_general\">Argatroban: Drug information</a></li><li><a href=\"topic.htm?path=argatroban-patient-drug-information\" class=\"drug drug_patient\">Argatroban: Patient drug information</a></li></ul></div></div>","javascript":null}